Skip to main content
Professional Technical IVT

MACE

Pronunciation: mayss

Also written as: MACE — Major Adverse Cardiovascular Events

A composite endpoint commonly used in cardiovascular clinical trials encompassing major adverse cardiovascular events.

Full Definition

Major adverse cardiovascular events (MACE) is a composite endpoint frequently used in cardiovascular research and clinical trials to assess the overall cardiovascular risk and treatment efficacy. While the exact definition can vary between studies, MACE typically includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Some studies expand this to include additional endpoints such as urgent revascularization, hospitalization for heart failure, or other cardiovascular events. The use of composite endpoints like MACE allows researchers to capture the overall impact of interventions on cardiovascular outcomes while maintaining statistical power in clinical trials. When reporting MACE results, it's important to specify which specific endpoints were included in the composite.

Usage

Usage note: MACCE (Major Adverse Cardiac and Cerebrovascular Events) is sometimes used interchangeably but may have slightly different endpoint definitions.

In Context

  • "The primary endpoint of MACE occurred in 12% of patients in the treatment group versus 18% in the placebo group." — Clinical trial manuscript
  • "Long-term follow-up demonstrated a significant reduction in MACE among patients who underwent complete revascularization." — Medical journal article

Also known as

major adverse cardiovascular events MACCE major adverse cardiac events

Don't confuse with

MACCE cardiovascular death primary endpoint

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON